Adina Zhang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Skeletal Muscle

Systematic Review

Coronavirus Disease

Top Venues

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)